Scinovex
articleTop 1% cited

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>

JAMA · 1999 · Vol. 282(7) · pp. 637–637
Bruce Ettinger

Abstract

In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture.

Bone health and osteoporosis researchEstrogen and related hormone effectsBone Metabolism and DiseasesMedicineRaloxifeneOsteoporosisSelective estrogen receptor modulatorPlaceboRandomized controlled trialAdverse effectInternal medicineStrontium ranelateTamoxifen

MeSH terms

AdultAgedEstrogensFemaleHumansMiddle AgedPiperidinesRadiographyRiskBone DensityOsteoporosis, PostmenopausalSpinal FracturesRaloxifene Hydrochloride
Citations
3,366
FWCI
178.07
field-weighted impact
References
32
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.